Baudax Bio (BXRX) Stock Price, News & Analysis

Company Overview

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.03
• 52-Week Range: $0.01 to $3.47
• Volume: 310,872 shs
• Average Volume: 281,029 shs
• Market Capitalization: $1.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BXRX Stock Analysis - Frequently Asked Questions

How were Baudax Bio's earnings last quarter?

Baudax Bio, Inc. (NASDAQ:BXRX) announced its quarterly earnings results on Wednesday, August, 16th. The company reported ($1.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.04) by $0.55.

When did Baudax Bio's stock split?

Baudax Bio shares reverse split on the morning of Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Vanguard Dividend Appreciation ETF (VIG), Vanguard Total Stock Market ETF (VTI), iShares Russell 1000 Growth ETF (IWF), Schlumberger (SLB), ARK Innovation ETF (ARKK), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/16/2023
• Today: 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BXRX
• CIK: 1780097
• Web: www.baudaxbio.com
• Phone: 484-395-2440
• Fax: 484-395-2471
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($9.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-58,790,000.00
• Net Margins: N/A
• Pretax Margin: -18,950.64%
• Return on Equity: N/A
• Return on Assets: -175.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 0.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($14.93) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 52,460,000
• Free Float: 52,408,000
• Market Cap: $1.14 million
• Optionable: Not Optionable
• Beta: 1.57